Clinical and research programs continue to advance, supported by year-to-date cost efficiencies
SAN DIEGO , Feb. 4, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases,...
SAN DIEGO , Dec. 5, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening...
Results Support the Further Investigation of the Hemopurifier in Long COVID
Clinical and research progress continues alongside substantial cost reductions.
SAN DIEGO , Nov. 7, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases,...
Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Aethlon Medical...
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - October 8, 2025) - Investorideas.com, a go-to investing platform covering biotech and medtech stocks releases an industry snapshot looking...
SAN DIEGO , Oct. 7, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD) today provided observations on the preliminary changes in extracellular vesicle (EV), microRNA...
SAN DIEGO , Sept. 4, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer...